Atrinsic Inc. (NASDAQ:PTIX) Short Interest Update

Atrinsic Inc. (NASDAQ:PTIX) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totaling 50,768 shares, a decline of 17.7% from the December 15th total of 61,712 shares. Based on an average daily trading volume, of 53,322 shares, the days-to-cover ratio is currently 1.0 days. Approximately 2.9% of the company’s stock are sold short. Approximately 2.9% of the company’s stock are sold short. Based on an average daily trading volume, of 53,322 shares, the days-to-cover ratio is currently 1.0 days.

Atrinsic Stock Performance

PTIX opened at $0.59 on Monday. Atrinsic has a one year low of $0.26 and a one year high of $14.28. The company has a market cap of $1.14 million, a P/E ratio of -0.07 and a beta of 0.51. The business’s 50-day simple moving average is $1.47 and its 200-day simple moving average is $2.63.

Atrinsic (NASDAQ:PTIX) last announced its quarterly earnings results on Wednesday, November 26th. The company reported ($0.47) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Atrinsic in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Atrinsic Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.